Molecular imaging: What picture does it paint for future oncology?

Drug Discovery Today

Volumn 7, Issue 14, 2002, Pages 741-743

  Price, Pat ^a   Jones, Terry ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ISOTOPE; LIGAND; TRACER;

CANCER CHEMOTHERAPY; DRUG INDUSTRY; EDITORIAL; ELECTRON; HUMAN; IMAGING; KINETICS; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MEDICINE; ONCOLOGY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; DRUG DESIGN; NEOPLASM;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG INDUSTRY; HUMAN; MEDICAL ONCOLOGY; NEOPLASMS; HUMANS;

EID: 0036629258     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02358-9     Document Type: Editorial

References (4)

1. The imaging science of positron emission tomography
2. In vivo pharmacokinetics and pharmacodynamics in drug development using positron emission tomography (PET)
3. Preliminary studies of computer aided ligand design for PET
4. The Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients